Marc Voigt
Net worth: 567 275 $ as of 31/05/2026
Net worth: 567 275 $ as of 31/05/2026
Marc Voigt currently works at Immutep Ltd., as Chief Executive Officer & Executive Director, Immutep SAS, as Chairman-Supervisory Board & President from 2015, Immutep GmbH, as Co-Managing Director, and Pharma-Lizenz-Club Deutschland, as Member.
Mr. Voigt also formerly worked at Elanix Biotechnologies AG, as Vice Chairman-Supervisory Board, Medical Enzymes AG, as Director-Finance, Legal & Business Development from 2001 to 2006, Allianz SE, as Principal from 2001 to 2009, Revotar Biopharmaceuticals AG, as Chief Financial Officer from 2003 to 2006, Allianz Versicherungs AG, as Principal, caprotec bioanalytics GmbH, as MD, Chief Operating & Financial Officer, and Immutep GmbH, as General Manager-European Operations.
Mr. Voigt received his Masters Business Admin degree from Freie Universität Berlin.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMMUTEP LTD 1.01% | 18/03/2026 | 1,48,77,395 ( 1.01% ) | 567 275 $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| IMMUTEP LIMITED | Chief Executive Officer | 09/07/2014 |
Pharma-Lizenz-Club Deutschland | Corporate Officer/Principal | - |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Develops T-cell response-based immuno therapeutics for the treatment of cancer and infectious diseases | Chairman | 18/11/2015 |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Chief Executive Officer | - |
| Companies | Position | End |
|---|---|---|
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Director of Finance/CFO | 02/01/2006 |
Revotar Biopharmaceuticals AG
Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory drugs | Director of Finance/CFO | 02/01/2006 |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Corporate Officer/Principal | - |
| ELANIX BIOTECHNOLOGIES AG | Director/Board Member | - |
caprotec bioanalytics GmbH
caprotec bioanalytics GmbH BiotechnologyHealth Technology Commercializes Capture Compound Mass Spectrometry technology | Director of Finance/CFO | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 11 |
|---|---|
Allianz SE
Allianz SE Multi-Line InsuranceFinance Provides property, casualty, life and health insurance and asset management services | Finance |
Immutep Ltd.
Immutep Ltd. BiotechnologyHealth Technology Engages in the development of anti-cancer therapeutics | Health Technology |
Elanix Biotechnologies AG
Elanix Biotechnologies AG BiotechnologyHealth Technology Develops and commercializes products for acute wound care, dermatological, and gynecological applications | Health Technology |
Revotar Biopharmaceuticals AG
Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory drugs | Health Technology |
Allianz Versicherungs AG
Allianz Versicherungs AG Multi-Line InsuranceFinance Provides motor, property, liability and accident insurance services | Finance |
Freie Universität Berlin
Freie Universität Berlin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
caprotec bioanalytics GmbH
caprotec bioanalytics GmbH BiotechnologyHealth Technology Commercializes Capture Compound Mass Spectrometry technology | Health Technology |
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Develops product family based on amino acid depleting enzymes | Health Services |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Develops T-cell response-based immuno therapeutics for the treatment of cancer and infectious diseases | Health Technology |
Pharma-Lizenz-Club Deutschland | |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Develops novel immunotherapy treatments for cancer and autoimmune disease | Health Technology |
Select your edition
All financial news and data tailored to specific country editions